With the global continuous glucose monitoring (CGM) market projected to reach $13.4 billion by 2025, companies like Abbott (ABT) and DexCom (DXCM) are leading the charge in providing real-time glucose monitoring solutions for diabetes patients. In Q1 2026, Abbott’s CGM sales were $2 billion, marking a 7.5% year-over-year increase, while DexCom reported significant growth in international markets, particularly in France and Canada.
Abbott’s FreeStyle Libre system has established itself as a global leader in CGM, with approximately 10-12 million users and an estimated long-term potential market of 70-80 million. Meanwhile, DexCom is expanding its reach, with over one million users connected to automated insulin delivery systems and plans for broader international product launches by late 2026. Year-to-date, ABT shares have decreased by 25.6%, while DXCM shares have increased by 4.1%.
Overall, both companies are poised for future growth amid varying short-term challenges. DexCom is anticipated to benefit from heightened CGM demand and new product launches, while Abbott continues to face volatility in diagnostics and dilution risks from recent acquisitions.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
